Capecitabine in Combination with Endocrine Therapy as Maintenance Therapy after Bevacizumab Plus Paclitaxel Induction Therapy for Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: KBCSG-TR1214

SIMPLE SUMMARY: To investigate a possible treatment strategy for hormone receptor (HR)-positive, HER2-negative advanced and/or metastatic breast cancer (AMBC), we investigated the clinical usefulness of adding capecitabine to maintenance endocrine therapy after induction chemotherapy and the efficac...

Descripción completa

Detalles Bibliográficos
Autores principales: Masuda, Norikazu, Yoshinami, Tetsuhiro, Ikeda, Masahiko, Mizutani, Makiko, Yamaguchi, Miki, Komoike, Yoshifumi, Takashima, Tsutomu, Yoshidome, Katsuhide, Tsurutani, Junji, Iwamoto, Mitsuhiko, Fujisawa, Fumie, Yasojima, Hiroyuki, Yamamura, Jun, Morishima, Hirotaka, Aki, Fuminori, Yamada, Tomomi, Morita, Satoshi, Nakayama, Takahiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8430728/
https://www.ncbi.nlm.nih.gov/pubmed/34503209
http://dx.doi.org/10.3390/cancers13174399

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8430728/
https://www.ncbi.nlm.nih.gov/pubmed/34503209
http://dx.doi.org/10.3390/cancers13174399

Ejemplares similares